- AbbVie, Gilead, Janssen dazzle with Hep C data
- Merck data shake up all-oral hepatitis C race
- AbbVie finds a PEARL of great price with ABT-450 combo in hepatitis C
- Gilead seeks FDA's OK for 'breakthrough' ledipasvir/sofosbuvir combo
COMMENT Other Informa Comment
- Leadership lesson: How to slim down and shape up, Kress style
- INTERVIEW: Dr Reddy's CEO on the 'windshield and rear view mirror'